Studies: Two new drugs benefit Type 2 diabetics

06/11/2006 | Wall Street Journal, The

At an American Diabetes Association annual meeting, Merck released data showing its Januvia lowered blood glucose levels in Type 2 diabetics while Pfizer showed its inhaled insulin treatment Exubera was effective at lowering or maintaining blood sugar levels in Type 1 and some Type 2 diabetics, both without serious side effects. Merck hopes to receive FDA approval for Januvia in October, while a similar drug, Novartis' Galvus, is expected to be approved by early 2007.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL